Widespread Use of Weight-Loss Drugs Redefines Health, Beauty, and Access

As 1 in 8 Americans and 1 in 7 Britons embrace drugs like Ozempic, questions about equity, safety, and societal impacts intensify.

GLP-1 drugs like Ozempic and Wegovy are now widely available, with no significant shortages reported as of early 2025.
The drugs are reshaping societal norms, fueling the resurgence of ultra-slim beauty standards and increasing obesity stigma.
High costs and limited insurance coverage create significant disparities in access, favoring wealthier individuals over lower-income groups.
Emerging research highlights potential broader health benefits, including applications for Alzheimer’s, depression, and addiction treatment.
Concerns persist about long-term dependency, experimental uses such as microdosing, and the implications for traditional weight management practices.